NYSE:PFEPharmaceuticals
Pfizer (PFE) Wins EU Approval For Keytruda And Padcev In Bladder Cancer
Pfizer (NYSE:PFE) and Merck received European Commission approval for the Keytruda plus Padcev regimen in perioperative bladder cancer.
The decision covers patients who are ineligible for cisplatin based chemotherapy across the European Union.
This is the first and only PD 1 inhibitor plus antibody drug conjugate combination cleared in the EU for this indication.
The approval highlights how Pfizer is leaning on oncology and antibody drug conjugates as it reshapes its portfolio. For...